ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: GlobeNewswire
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have been enrolled; topline results anticipated in Q2 2027Ended the third quarter with $272 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2025, and provided regulatory and clinical updates. “The Phase 2 REGEN-007 full results recently presented at ASN Kidney Week further strengthen the body of evidence supporting
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- ProKidney GAAP EPS of -$0.12 beats by $0.02, revenue of $0.22M beats by $0.18M [Seeking Alpha]Seeking Alpha
- ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates [Yahoo! Finance]Yahoo! Finance
- ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025GlobeNewswire
- ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare ConferenceGlobeNewswire
- ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025GlobeNewswire
PROK
Earnings
- 11/10/25 - In-Line
PROK
Sec Filings
- 11/19/25 - Form EFFECT
- 11/14/25 - Form 4
- 11/12/25 - Form 144
- PROK's page on the SEC website